Four years since the start of the pandemic, we now have a good understanding of what Long COVID does. More of a mystery has been why it happens. New research is starting to find answers.
New research by the London School of Hygiene & Tropical Medicine and the Vaccine Impact Modelling Consortium underlines the global inequality in access to HPV vaccines.
Recently approved malaria vaccines have reinvigorated hopes of eliminating the disease, but other innovations are in development that could further bolster these efforts.
Research shows that rapid antigen tests are performing as well at detecting the most recent dominant variants as they did with the earliest strains in the COVID-19 pandemic.
A new Gavi market shaping roadmap for HPV vaccines showcases how partners, manufacturers and countries must work together to secure a sustainable supply over the next decade.